📰 Planned Phase News
Page 2 - Planned Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planned Phase. Real-time updates on events, politics, business and more.
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
March 30, 2022
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without...
March 22, 2022
22.03.2022 - BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. ...
March 18, 2022
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M
March 17, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...
March 17, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...
February 9, 2022
09.02.2022 - -FC2 Prescription Business Entering 6th Year of Growth - -FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway- -Company Enters into Clinical Trial ...
November 1, 2021
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
November 1, 2021
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...